• McKesson Corporation has reported past first-quarter 2026 results, with sales rising to US$105.38 billion from US$97.83 billion a year earlier, while net income declined to US$614 million and diluted EPS from continuing operations fell to US$5.15 from US$6.25.
• This combination of higher revenue but lower profitability highlights ongoing cost and margin pressures that could be important for how investors interpret McKesson's long-term earnings profile.
• We’ll now examine how McKesson’s higher sales but weaker earnings reshape the company’s investment narrative and future earnings assumptions.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

McKesson Investment Narrative Recap

To own McKesson, you have to believe in its role as a core infrastructure player in the pharmaceutical supply chain, benefiting from rising drug volumes and complex logistics. The latest quarter, with higher sales but weaker earnings, underlines that the key short term catalyst remains margin stability, while the biggest risk continues to be pressure on profitability from costs and pricing. So far, this earnings miss does not appear to fundamentally change that risk balance.

Among recent announcements, the July 2026 dividend increase to US$0.94 per share stands out alongside this softer quarter, because it reinforces management’s confidence in cash generation even as near term earnings face margin pressure. For investors watching catalysts, the combination of resilient capital returns and recent earnings volatility raises important questions about how sustainably McKesson can defend its margins in the face of evolving healthcare pricing and policy trends.

Yet beneath the higher sales and rising dividend, investors should be aware of the growing regulatory risk around drug pricing and healthcare costs...

McKesson's narrative projects $499.3 billion revenue and $6.1 billion earnings by 2029. This requires 7.4% yearly revenue growth and about a $1.3 billion earnings increase from $4.8 billion today.

Uncover how McKesson's forecasts yield a $941.40 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span a wide range, from about US$827 to more than US$2,282 per share, showing how far opinions can diverge. Against that backdrop, recent margin pressure in Q1 prompts you to weigh how regulatory and cost risks might influence McKesson’s ability to turn strong sales into durable earnings over time, and to compare several alternative viewpoints before forming your own view.

Explore 4 other fair value estimates on McKesson - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your McKesson research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.